INTRODUCTION
It is often stated that, from a functional or biomarker point of view, the analysis of proteins trumps that of mRNA (e.g., using DNA microarrays), as 'activities' are what ultimately matter in a cell. However, systematic measurement and quantitation of enzymatic activities in a complex biological matrix, while clearly in the realm of proteomics, is a largely unpracticed specialty at the moment. Enzymatic activity is bringing about chemical change in a target, ranging from simple modifications to anabolic or catabolic reactions. In the literal sense, activity-based or functional proteomics would therefore entail profiling based on genuine activity readouts. Yet, in a typical mass spectrometry (MS)-based proteomic analysis, enzymes are simply looked at as 'proteins' that may or may not be physically present in certain locations and that may undergo temporal changes in concentration. Furthermore, many enzymes are present below the MS detection limits in a given sample and are therefore 'invisible' in traditional screens. As an alternative, the case could be made that, given sufficient substrate and time, and optimal assay conditions, catalytic or synthetic products may accumulate to levels that become readily detectable using some type of analytical technique. This may be particularly true for proteolytic enzymes, as they generate peptide products that are tailor-made for MS-based proteomic readouts.
Human cells produce well over 500 proteases 1, 2 . Although they all share one principal functionality, the lysis of peptide bonds, their biological roles differ greatly, ranging from digestion of food and discarded cellular proteins to more specific functions such as basic control mechanisms in the cell, orderly progression of physiological pathways and response to trauma, to name a few 1, 2 . Proteases have also been implicated in diseases, most notably in cancer where they may promote both tumor progression and suppression [3] [4] [5] . Typical assays monitor substrate conversion through simple colorometric or fluorophoric readouts 6, 7 that are easily performed in parallel but not so easily multiplexed. It is also difficult to measure 'compound' proteolytic activities that degrade a substrate, either in unison or sequentially. Examples of sequential peptide degradation have unexpectedly been observed in recent oncopeptidomics studies [8] [9] [10] . In these studies, subsets of serum peptides provided class discrimination between patients with different types of solid tumors and control individuals without cancer. Nearly all relevant peptides sorted into about a dozen nested sets of sequences; each is the result of exopeptidase activities that confer cancer-type-specific differences superimposed on the proteolytic events of the ex vivo coagulation and complement degradation pathways 9 .
On the basis of those findings, we reasoned that isotopically labeled ( 13 C and/or 15 N) peptides, such as FPA (fibrinopeptide A) or C3f, or any synthetic peptide containing a known endopeptidase or exopeptidase target sequence for that matter, would allow to accurately track degradation over time when added to serum or plasma, or to any complex matrix containing active proteases. The kinetics and/or the resulting patterns could then perhaps be used to compare defined peptidase activities between individual proteomes of two or more (groups of) biological samples. Ideally, such a test should allow a straightforward analysis in a highly reproducible and intersample comparable manner. To address this need, we have developed a protocol to measure de novo peptide breakdown in large numbers of biological samples using matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) MS, with relative quantitation of the metabolites by comparison with double-labeled, nondegradable reference peptides (consisting of D-amino acids only), spiked into the samples at the same time as the substrate(s) to reflect adsorptive and processing-related losses 11 . The full array of metabolites is then quantitated (coefficients of variation (CVs) r15% over multiple replicates) and the results subjected to kinetic analysis and univariate or multivariate statistical analysis 11 .
As shown in Figure 1 , the workflow of the protocol presented herein consists of eight interlocking modules. Modules 1 and 2 involve preassay activities, such as sample collection and handling (module 1; Steps 17-35), before parallel incubation with exopeptidase substrate(s). Samples can be bodily fluids, tissue or cell extracts, secreted proteins or fractions obtained from nondenaturing column chromatography of any of the above complex substrates, they may consist of a nondegradable, highly ionizable component to which one, two or three cleavable amino acids have been attached, and the removal of which could be readily measured by even the most simple of MS platforms. Endopeptidase substrates, on the other hand, may contain a multi-amino acid, cleavable linker that corresponds to a known target sequence (e.g., from P3 to P3¢) of the protease under study. We speculate that degradation of such substrates will be easier to quantify, in multiplexed assays, and may allow examining key elements of fundamental biological processes such as development, cell-cycle progression, apoptosis, clotting and wound healing, as well as monitoring disease (e.g., cancer) and the presence of infectious disease agents in bodily fluids, and evaluating efficacy of novel protease inhibitors. 
MATERIALS

REAGENTS
. . Custom synthetic peptides (e.g., C3f is given in Table 1 Mono-isotopic masses of singly protonated peptides are listed.
BOX 1 | PEPTIDE QUANTITATION STEPS
1. Reconstitute the newly synthesized peptides based on the estimated amount and concentration in 30% acetonitrile, 0.1% FA to obtain B10 mg ml À1 . 2. Transfer a 1-ml aliquot to a 0.5-ml Eppendorf tube and dry using a speed vacuum. 3. Send the sample to a service laboratory for amino-acid analysis. 4. Recalculate the concentration of the peptide stock based on the amino-acid analysis quantitation result. 5. Adjust some of the stock solution to 100 pmol ml À1 in 30% acetonitrile, 0.1% FA. Store both stocks at À20 1C. 6. Prepare a mixture of all the reference peptides with a final concentration of 10 pmol ml À1 for each peptide (10 peptides in the C3f-ladder).
. All parts should be machined in aluminum and clearly anodized ( Fig. 2 and Supplementary Fig. 1 ). Custom side-magnet rack Designed to have seven long magnets (see EQUIPMENT) at the sides of the vials of the 96-well plate. Parts should be machined in clear Lexan ( Fig. 2 and Supplementary Fig. 2 ). Custom bottom-magnet rack Designed to have 96 disk magnets (see EQUIPMENT) at the bottoms of the vials of the 96-well plate. The parts should be machined in clear Lean plastic with standard 96-well plate dimensions ( Fig. 2 and Supplementary Fig. 3 ).
PROCEDURE
Testing new candidate exoprotease substrates TIMING (Steps 1-5) B2 to 14 h 1| Thaw an aliquot of human serum from Sigma (250 ml) on wet ice for an hour.
2| During this time, prepare fresh reagents (see REAGENTS SETUP).
3| Analyze substrate peptides before proteolysis (zero time point) using 100 pmol of the peptide, which will be used in a particular assay (e.g., C3f_ 13 C) to verify the molecular weight (m/z value) (Box 3). ? TROUBLESHOOTING 4| Select preliminary incubation time points to test. Generally, two preliminary incubation time points are selected, for instance 15 min and 1 h. ? TROUBLESHOOTING 5| Prepare samples for the preliminary test time points, as described in Box 3, and evaluate the selected time points. On the basis of the results (extent of degradation or lack thereof) after these incubations, a decision should be made about which additional time points to select. For example, if many or all rungs of the expected ladder are observed after 15 min, incubations of the peptide in serum will also be carried out for 5 and 30 min. If there was degradation only after 1 h, additional time points at 30 min and 2 h will be investigated. Lastly, if no degradation was observed after 1 h, incubation periods of 3 h, 6 h and overnight should be tested (Fig. 3) . m CRITICAL STEP Cover the samples in the eight-tube strip with its eight-dome cap; strip to avoid evaporation and precipitation. m CRITICAL STEP Incubate reactions at RT.
6|
After the best time point(s) are established, synthesize isotopically labeled versions of the peptides judged to be optimal substrates, as well as synthesize a series of doubly labeled, nondegradable D-peptides (reference peptides consisting of D-amino acids) that correspond to each rung in the degradation ladder.
7| Quantitate the newly synthesized peptides using amino-acid analysis, as described in Box 1. Testing new labeled exoprotease substrates and reference peptides in serum pools TIMING (Steps 8-16) B2 to 15 h 8| Prepare pools of the clinical groups that will be studied. First transfer an equal amount from each individual sample type into a large vial. Then, mix the newly created pool by pipetting up and down couple of times. Prepare 20 ml aliquots of the pool and freeze samples in À80 1C. m CRITICAL STEP Pools must be prepared on wet ice.
9| Thaw an aliquot of the pool on wet ice. ! CAUTION Leftover sample should not be frozen for further use.
10|
Repeat Steps 2-4 with the thawed aliquots (exactly as performed for the unlabeled peptide) to confirm that the same degradation time and concentration conditions apply to the labeled version.
Incorporating the corresponding reference D-peptides into the assay 11| Transfer 20 ml of thawed pool of reference D-peptides (Table 1 ) into a well of a 0.2-ml eight-tube strip.
12| Add 10 ml of 0.2 pmol per ml of the reference peptide mix (see REAGENTS SETUP) to yield a total amount of 2 pmol. ! CAUTION Change tips in between each step to avoid contamination.
13| Add 10 ml of 10 pmol per ml of the substrate (degradable labeled peptide) (see REAGENTS SETUP) to yield a total amount of 100 pmol. ! CAUTION Change tips in between each step to avoid contamination.
14| Cap the eight-tube strip with its eight-dome cap strips and then start incubation at RT.
15| After incubation, follow Box 3. See Figure 4 for typical results. 
BOX 3 | MANUAL SOLID-PHASE EXTRACTION
A 'time-zero' data point is taken using 100 pmol of the peptide under study to verify the MH + value. 1. Transfer 20 ml of the thawed serum (or plasma) to a well of a 0.2-ml eight-tube strip.
2. To the sample, add 10 ml of 10 pmol per ml of the substrate (labeled/unlabeled) solution to yield 100 pmol. m CRITICAL STEP Change tips in between each step to avoid contamination. 3. Immediately, add 5 ml of the pre-washed Dynabeads and mix it three times using your pipette tip. 4. Place the eight-tube strip on a magnetic plate to separate the peptide-bound Dynabeads from the sample. 5. Remove and discard the supernatant. 6. Wash the Dynabeads by adding 200 ml of 0.1% TFA and mixing it by moving the eight-tube strip back and forth eight times. 7. Aspirate and discard the washing solution. 8. Repeat the wash step (steps 6 and 7) one more time. 9. After removing the wash solution, resuspend the beads with 6 ml of 50% acetonitrile by pipetting the beads up and down quickly ten times. 10. Transfer 5 ml of eluate into a new well. 11. Add 10 ml of matrix solution to the well containing 5 ml of the eluate. 12. Mix the matrix with the eluate by pipetting up and down. 13. Aspirate 1 ml of the mixture and spot on a MALDI plate. 14. After the spot has crystallized, insert the plate into a MALDI-TOF mass spectrometer. 15. Select the method 'ExoproteaseAssay.par' detailed in Box 5 (Reflectron mode method created in house) in the FlexControl program. 16. Acquire a spectrum and save it in a new created folder to be stored for future reference. 17. Open the FlexAnalysis program and choose your newly created file. 18. You should be able to see the parent peptide peak among the endogenous serum peptides.
! CAUTION If 100 pmol is insufficient, you must adjust the amount of peptide and repeat the above steps until the proper concentration is established. This may vary among peptides. 20| Spin the SST tubes in a clinical centrifuge at 1,400-2,000g for 10 min at RT.
21| Label 4 ml cryovials.
22| Transfer the serum (upper phase) to the appropriately labeled 4 ml cryovials. The volume of serum per cryovial should be B1 ml. These cryovials will be called 'source vials' throughout this protocol.
23|
Immediately store all serum samples at À80 1C. Avoid freeze-thaw cycles. Transport the serum samples to the MS laboratory on dry ice.
24| Enter all sample information into the LIMS before the samples arrive at the lab. Fill out the necessary information for each specimen (see EQUIPMENT SETUP). Barcode labels for the original source vial tubes should be created automatically every time the sample information is submitted. Keep labels organized in the same order as the samples to make the process easier. Prepare a source vial list for verification while labeling the source vials.
25| Label the source vials while they are frozen on dry ice. Note that the barcode labels are designed for small 0.5 ml microcentrifuge tubes and not for bigger vials. Labels will not overlap on the back of larger tubes; hence, it is difficult for the labels to stay attached, especially when there is water condensation on the surface of the frozen vials. For those reasons, it may be necessary to wipe the tubes dry with a piece of paper tissue before attaching the label and adding a piece of tape on the top to secure the label effectively. m CRITICAL STEP Always double check sample IDs on source vials; match the sample information associated with their barcode labels in the database.
26| Store the labeled source vials in the À80 1C freezer in cardboard freezer boxes with temporary labels indicating the project and date, and marked 'source vials to be aliquoted.' If more than one source vial is received for each specimen, then use only one of them for aliquoting. Place the remaining source vials in separate boxes temporarily labeled with a tape with the project name, date and marked 'source vials for permanent storage.' These vials will be entered later into bar-coded boxes and those boxes will be added to the inventory. ' PAUSE POINT Serum source vials can be kept frozen for at least 5 years at À80 1C.
27| Take the boxes containing the source vials to be aliquoted out of the freezer and place the vials on dry ice. m CRITICAL STEP The samples should remain frozen while the bar codes for the aliquots are being generated. 28| Scan the bar code of the first source vial to be aliquoted. A 'Specimen ID' will be generated if the database recognizes the sample correctly. Select the volume of serum in the source vial. Indicate the volume of the aliquots (50 ml) and select the number of aliquots to be prepared based on the volume of sample available. New labels will be printed for all of the aliquots created. If sufficient sample is available, generate nine aliquots of 50 ml each per specimen (source vial). Keep adding the specimens until the list has been filled.
29|
Label the clean 0.5 ml microcentrifuge tubes with the aliquot barcode labels and organize them according to the order of the original source vials. If available, use 12 Â 8-hole plastic racks for 0.5 ml tubes or place the labeled tubes directly in the aliquot racks of the Tecan liquid handler 12 . Generally, tubes have to be organized in eight rows of nine tubes. From each set of tubes, eight will be placed in temporary 'aliquots for permanent storage' boxes and one aliquot (normally, aliquot no. 1) will be placed in a separate box marked 'to be run with Tecan' and dated.
30| Place the source vials on wet ice once all the aliquot tubes have been labeled, organized and checked. Use big-flat ice buckets to place the samples in the same order; they will be aliquoted and let thaw for 60-90 min. m CRITICAL STEP Verify that the source vials and their associated aliquots match before proceeding with the aliquoting process to avoid thawing the serum of source vials that were not planned to be aliquoted.
31| Load the clean, newly bar-coded aliquot tubes in the aliquot racks (16 rows of 9 aliquots of each sample). Tubes have to be placed so that the lids rest against the back lip of the rack, allowing the tubes to be closed easily once they have been aliquoted with serum. Place the aluminum aliquoting racks in the robot carriers in the layout as indicated in Figure 2a and then load the rack with the source vial samples in the same order as the aliquot tubes. Keep the source vial racks on wet ice to maintain the serum as cold as possible before the aliquoting process begins.
32| Open the Gemini program by clicking on the icon located on the PC desktop. Run the Gemini aliquot program or manually perform the aliquoting using microcentrifuge micropipettes. Aliquoting process can be carried out automatically or manually, as long as all the tubes are carefully organized.
33|
Close the tubes and put them in their corresponding foam inserts and boxes on dry ice, to be temporarily stored at À80 1C in the prelabeled temporary boxes. The boxes' numbers and dates will allow the samples to be correctly identified during later steps. This process must be kept as short as possible to avoid exposure of the samples to RT. ' PAUSE POINT Serum aliquots can be kept frozen for at least 5 years at À80 1C.
34|
Create labels for the boxes for permanent storage of the aliquots. Calculate how many boxes are required to store all the created aliquots, dividing the total number of aliquots by 128 (maximum number of aliquots per box) and rounding up to the next whole number. For this purpose, new 'Containers' will be created in the 'Inventory' section of the LIMS. During this process, barcode labels for the upper and lower foam inserts, for the entire freezer box, and for the freezer racks will be created. Place the label on the center of the outer part of the box. The label for the upper foam insert goes in the upper left corner of the inner part of the box and that for the lower foam insert at the lower right corner of the inner part.
35| Scan the aliquots to be placed in their permanent locations in the prelabeled boxes, using one temporary box at a time. Enter the aliquot's permanent location in the inventory section of the LIMS. Scan the samples and place them in the physical location assigned by the database. (A1 is the top left spot in the foam inserts.) In a similar manner, fill the other containers: place aliquots inside foam inserts, foam inserts inside cardboard boxes, boxes inside freezer racks, racks inside freezer shelves, shelves inside freezer and freezer inside room. Keep all aliquots frozen on dry ice at all times. m CRITICAL STEP Make sure that all aliquots are placed in their proper permanent storage box. From this time on, information on where the specimens are will be stored only in the LIMS system. ' PAUSE POINT Serum aliquots can be kept frozen for at least 5 years at À80 1C.
Set up of the robot run TIMING B4 h 36| Scan the bar codes of the aliquots to be run and make a list of their barcode identifiers. Save the list with the project name and date as a plain text file (.txt in NotePad or TextEdit). Place all aliquots frozen on dry ice at all times. These aliquots (normally aliquot no. 1 of each sample) should be in temporary 'to be run' boxes after the aliquoting step.
37| Open the randomization software, MALDI autoexecute generator v 3.0.exe 12 , and indicate the number of samples to be run. The maximum number of serum aliquots that can be run for each MALDI plate is 96. If more than 96 samples are added, the program will create two or more MALDI plates. generated, together with the calibrant locations. The layout generated by the randomization software does not represent the 96-well plate where the serum samples will be placed for the solid-phase extraction. Instead, it represents the 384 spots corresponding to the MALDI target plate, showing where the 96 serum samples plus the calibrants will be spotted for MS analysis.
39| Next, the program will ask where to save the output file (Autoexecute file), which contains the set of instructions for the FlexControl program to run the mass spectrometer automatically.
40| Print the target layouts (generated in Step 38), as they will be needed during the organization of the randomized serum aliquots and will later be filed in the corresponding record's folder.
41|
Locate and organize the aliquots in 96-well plastic racks (precooled on dry ice for 10 min) according to the randomized order shown in the target layouts. Always verify the sample list and the layouts to make sure that listed samples, information in the layout and tube identifications match. Take the boxes with the aliquots already organized out of the À80 1C freezer and put them in big-flat ice buckets containing dry ice. Then, take aliquots from the boxes and put them in 96-well plastic racks following the randomized order. Keep all aliquots frozen on dry ice at all times. m CRITICAL STEP This is a very tedious but important step. Any error in properly organizing the samples in the randomized order will affect the whole experiment. ' PAUSE POINT Serum aliquots can be kept frozen at least 5 years at À80 1C.
42|
Transfer output files (Autoexecute files) to the MALDI-TOF PC (for instance, C:\data\methods\autoexecute files). m CRITICAL STEP Print Autoexecute files to keep them in the records.
43| Schedule the runs of clinical samples. Check the following: Are all the aliquots to be run randomized, are they organized in plastic racks, are they double-checked so as to ensure that each aliquot is in the correct position on the correct plate and are they placed in the À80 1C freezer?; Have Autoexecute files and printouts been generated and transferred to the appropriate folders?; Are all the reagents and materials available for the assay?
44| Start setting up the robot during the morning of the day of the runs by cleaning the Tecan liquid handler, degassing the water that the robot will use for the runs, ensuring the waste container has sufficient room to receive what the assay will discard. Also, flush the system twice. m CRITICAL STEP There should be no visible bubbles traveling the lines throughout the flushes. Flush until no bubbles remain.
45| Perform a system performance verification experiment (see Box 4) on the morning of, or the day before, analysis of each sample set submitted for activity assaying.
Automated solid-phase extraction TIMING B6 h 46| Thaw the 48 serum samples, taking the first plastic rack (containing aliquots in the randomized order) from the À80 1C freezer and transferring the samples to wet ice for about 60 min, carefully keeping the same order of the samples as in the plastic racks.
47| Prepare reagents and the calibrants (see REAGENTS SETUP).
m CRITICAL STEP Calibrants and some of the reagents must be prepared the day of the assay.
48| Mix the Dynabeads gently until completely dispersed. Using an 8-well strip of 0.2-ml thin-wall tubes, put 75 ml of magnetic beads in each of the 8 wells and place in the proper holder on the robot deck (Fig. 2b) .
49| Add fresh 0.1% TFA (see REAGENTS) to the TFA trough on the robot (Fig. 2b) .
50| Prepare a 96-well half-skirted microtiter plate: the first column should contain 100 ml of 50% acetonitrile in each well; the second column should contain 100 ml of the matrix. m CRITICAL STEP 50% Acetonitrile should be prepared fresh on the day of experiment.
51| Tightly seal the wells of the 96-well half-skirted microtiter plate with a piece of self-adhesive foil using a rubber roller. Attach the plate to the cooler rack with a piece of Parafilm wrapped around the microtiter plate and the inner part of the cooler rack, so that the plate will remain in place when the robot tips pierce the foil. Also, use four mini-binder clips attaching the cooling rack to the robot to prevent it from falling out of position. The cooler rack should be kept at À20 1C for several hours before it can be used for a clinical run. Note that the rack changes color with temperature making it easier to know whether it can be used for a run. (Fig. 2b) .
53| Transfer 20 ml from each aliquot (50 ml) to the proper well of a 96-well half-skirted microtiter plate. Note that only the first half of the microtiter plate contains serum samples. The second half will be used during the SPE automatic process. If prepared properly, the aliquots should have thawed in the same positions, as they will be placed in the microtiter plate; check corresponding randomization layout to make sure. m CRITICAL STEP Reactions must be prepared on wet ice.
54| Add 10 ml of the nondegradable reference peptide mix (see REAGENTS SETUP) to yield total of 2 pmol per reaction. m CRITICAL STEP Change pipette tips in between each sample to avoid cross-contamination.
55| Add 10 ml of the substrate (e.g., C3f-13 C) (see REAGENTS SETUP) to yield a total of 100 pmol per reaction. m CRITICAL STEP Change pipette tips in between each sample to avoid cross contamination.
56| Cover the 96-well plate with aluminum foil and incubate at RT for an appropriate time that has already been determined in Steps 4 and 5 (e.g., C3f-13 C requires 3 h incubation time).
57| Place the plate in the 'plate holder 1' position (Fig. 2b) .
58| After the incubation of reactions is complete, flush the robot one more time.
59|
Run the TECAN program. The robot will carry out the steps described in Box 2. m CRITICAL STEP This protocol can also be performed manually using 96-well plate holders, magnet racks and eight-channel multipipettes. However, the manual procedure is not recommended because of a lack of reproducibility. Prepare extra solution in case needed. 3. After the human serum (Sigma) has thawed, transfer 20 ml to the designated wells of 0.2 ml polypropylene 'Template III PCR' half-skirted, 96-well microtiter plate. To each serum sample, add 10 ml of 0.2 pmol per ml of the reference peptide mix (final amount ¼ 2 pmol). And then add 10 ml of 10 pmol/ml C3f_ 13 C (final amount ¼ 100 pmol) m CRITICAL STEP Sample preparation is done on wet ice. 4. Add 40 ml PBS to the remainder of empty wells. 5. Cover the 96-well plate with aluminum foil and incubate at RT for 3 h. 6. Place plate in the 'plate holder 1' position (Fig. 2b) . 7. Run the Gemini program (identical to the program that is run for the first half of the plate during the runs with clinical samples) (Box 2). 8. Remove the target and take it to the MALDI-TOF mass spectrometer. 9. Insert the MALDI target to be analyzed and select the method 'ExoproteaseAssay.par.' 10. Open the quality control Autoexecute template and edit the file (change the date and directory folder for saving the spectra). After editing the file, save a newly named file in the quality control Autoexecute file directory. 11. Open the edited Autoexecute file in the FlexControl program and run it. 12. Open the FlexAnalysis program after the run has finished. Open all the just-created quality control spectra using the 'open multiple spectra' function. 13. Overlay the 10 mass spectra and make sure that the overlay has a similar peptide complexity to that shown in Figure 5a . In addition, zoom in on the areas to see the degradation ladder (Fig. 5b ). 14. Calculate the ratios of the ion intensities of selected 'exogenous' degradation products (i.e., those derived from labeled, exogenous substrate) over the ion intensities of the corresponding reference peptides (sequences listed in MS TIMING B2 h 60| Insert the target plate to be analyzed in the MALDI-TOF mass spectrometer.
? TROUBLESHOOTING 61| Go to FlexControl, load the correct Autoexecute file and start the automatic run; this will perform the steps described in Box 5. The method referred to in this Autoexecute file should be updated to use the proper laser energy. The method is a Reflectron mode. m CRITICAL STEP The spectra can also be collected manually, going spot to spot and delivering sets of laser shots using the acquisition method optimized for the mass range (0.7-4 kDa). However, the manual procedure is very tedious and subject to bias as the operator aims the laser beam at an approximate location of choice.
62| Open the FlexAnalysis program after the run has been completed. Open all the spectra that have just been generated using the 'open multiple spectra' function and check that all the spectra have been created (by comparing the spectra with the Autoexecute file of the run).
63| Perform spectral analysis. This can be carried out through the 'Process' functions in FlexAnalysis. Alternatively, spectra can be translated to tab-separated text files that contain both x and y coordinates for each spectrum as separate columns using a custom-written macro (see EQUIPMENT). Once the spectra are in text format, they can be analyzed using different software.
Signal processing and quantitation TIMING (Steps 64-77) B8h
64| Convert mass spectra from binary format to ASCII files, containing two columns of data (x: m/z; y: intensity), by a custom-written macro in FlexAnalysis (Bruker Daltonics).
? TROUBLESHOOTING 65| Transfer data to MATLAB. Perform additional data processing with a custom script, 'qcealign' invoking qpeaks, a commercial program, to do smoothing, baseline subtraction, and peak labeling (see EQUIPMENT) 13 .
66| Use Signal Processing and Preview (SPP), a custom-built graphical viewer for spectra in ASCII format, to plot raw and processed spectra side by side to review the outcome of signal processing and to optimize parameters for Qpeaks 13 . The singlet width parameter should be set to 1,500, thereby specifying the resolution for processing. After processing, a peak table with normalized intensities, smoothed curve and baseline is created for each spectrum before alignment.
67| Use the custom algorithm, 'Entropycal,' to align sample data files to a reference file (a spectrum sum of all the sample files) using a minimum entropy algorithm by taking unsmoothed ('raw'), baseline-corrected data 13 . All peaks in the rows within (m/z) of the strongest peak at a given m/z value are binned together, and a spreadsheet containing the normalized aligned data is created for further data analysis.
68| Analyze this spreadsheet in conjunction with a custom visual interface for processed spectra, 'MassSpectraViewer' (see EQUIPMENT), to select only those peaks that correspond to the peptide ladder(s) resulting from peptide substrate degradation and to the spiked reference peptides 12 .
? 2. Start collecting the spectrum for the 0.7-4 kDa m/z: average 400 laser shots, delivered in four sets of 100 shots (at 50 Hz) to each of four different locations on the surface of the matrix spot (performing a spiral movement from one set to the next one). 3. Acquire spectra in reflectron mode geometry under 20 kV (16.45 kV during delayed extraction) of ion accelerating and À1.4 kV multiplier potentials and with gating of mass ions set to m/z 500. Delayed extraction is maintained for 80 ns to give time lag focusing after each laser shot. The effective laser energy delivered to the target is carefully controlled to be 16 mJ (±10%) per shot. The entire irradiation program is controlled using the instrument's 'Autoexecute' function, which automates the following steps: loading the correct spectrum acquisition method (with the optimized instrument settings), going to the right spot on the MALDI plate and delivering the four sets of 100 shots. 4. Keep collecting mass spectra for all of the samples and calibrants.
Importing data and creating experiments in GeneSpring 70| In the same location as the parameter file, Qcealign will have created a 'processed01.out' file; check this is present. This is the binned, aligned peak list for all samples.
71| Launch GeneSpring. From the File Menu, select 'Import Data.' In the resulting dialog window, navigate to and select the 'processed01.out' file. This is the binned, aligned peak list for all samples of the project; it is in the same location as the parameter file and it is created by Qcealign 13 . A dialog will appear asking for the name. Click 'Create a New Genome' and enter a name for the data set. For this example, we will use 'CancerStudy,' which is the name of the parent folder where the spectra are stored. Then click 'Next,' another window appears. The first column should be set to 'Gene Identifier.' The remaining columns should be set to Signal. Then, click next to dismiss this window. Another window will appear asking to import more data. As we have none, click next again. A window will appear, saying how many samples are created. Click 'Yes' to continue. Then GeneSpring will create an experiment. When you hit 'Next' to continue to create an experiment, a warning may appear saying that a column lacks a title. This means that there is an empty column. Scroll through and locate the empty column (usually the last column) and change the column designation from 'Signal' to 'Unused.' 72| To create an experiment, first type a name for the Experiment and hit 'Save.' We will name it 'CancerStudy' for our data set. Next, a window appears to set the different statistical properties of the experiment. Click on 'Normalizations.' As Qcealign already normalized the data, we need no normalizations. Remove all default normalizations using the 'delete' button and press 'OK.' Then, click on the 'Parameters' button. In the appearing window, enter the parameters you want to study. Click on 'New Parameter' and enter the clinical information for each sample. Enter 'Parameter1' as the name for the Column, accepting the default column properties. If the Parameter is Numeric (i.e., body weight), then set 'Numeric' to 'Yes,' otherwise leave it as 'No.' Similarly, set the value for 'Logarithmic' to 'Yes' or 'No,' depending on whether the data is in log scale. One can enter many parameters with which to analyze the data. Copy the parameter information from the spreadsheet obtained in Step 8. Press 'Save' when done. Statistical analysis 74| Depending on the number of samples available, two different strategies can be used to do the statistical analysis. In option A, training and test set are generated if sufficient samples are available. The training set is used to build a statistical model that later can be validated using the test set. In option B, the statistical analysis is carried out on the entire data set using a cross-validation approach. Test type should be set to 'Non-parametric' test. False discover rate should be set to 0.05. Multiple testing correction should be set to 'Benjamini and Hochberg False Discovery Rate.' There should be no post hoc tests. 
ANTICIPATED RESULTS
Although protease assays that use peptide substrates and a MALDI-TOF MS readout may be used to answer various questions in the health and life sciences (see Introduction); the only applications so far of the unique platform/method combination described here have been to screen for proteolytic activities in serum and plasma 8, 11 and to monitor purification of individual exopeptidases from cancer cell secretomes (unpublished). In contrast to C3f, a surprisingly large number of 'other' serum peptides that have been tested as candidate assay substrates did not degrade in serum or plasma, not even after prolonged incubations (unpublished observations). Only FPA (ADSGEGDFLAEGGGVR), FPA without the N-terminal Ala (FPA(-A): DSGEGDFLAEGGGVR), a peptide mapping to the C terminus of the clusterin betachain (Clus2: RPHFFFPKSRIV), and a peptide derived from alpha-1-antitrypsin (A1AT: LMIDQNTKSPLFMGKVVNPTQK) have proven utility as assay substrates at this time 11 . Substantial degradation of 100 pmol of any of the five aforementioned substrates can be anticipated within 15 min (FPA) to 15 h (FPA(-A)) after addition to 20 ml human control serum or plasma 11 . More specifically, the C3f-based system performance verification test described in Box 4 and Figure 5 should yield the indicated results after 1-3 h incubation, with CVs of normalized MS peptide-ion intensities of five selected metabolites (see Box 4) all below 15% over 10 technical replicates at fixed incubation times. This also applies to replicate assays using Clus2, FPA(-A) and A1AT peptides as substrates (2 h incubation for Clus2; 6-15 h for the others). FPA degrades within minutes after addition to serum, which makes accurate timing and reproducibility exceedingly difficult, especially when dealing with large sample sets, typically resulting in CVs 430%. This protocol has also been used to assay serum samples obtained from 48 patients with metastatic thyroid cancer and 48 gender-and age-matched healthy controls, and using three different peptide substrates (C3f, FPA(-A) and Clus2) in separate analyses. The full array of peptide metabolites (a de facto 26-member 'mini-peptidome') was then quantitated and subjected to multivariate statistical analysis and machine learning methods to ultimately yield class predictions with 94% sensitivity and 90% specificity 11 . It should be noted, however, that none of these 26 individual peptides comprising the assay degradome could, by itself, be used as a quantitative 'biomarker' (in the form of a MALDI-TOF MS-generated ion intensity signal) to completely distinguish all the cancer patients from healthy controls. At best, the ion intensities of certain peptide peaks, as for instance, for the three C3f degradation products in the color-coded spectral overlays shown in Figure 6 , are on average higher in one particular group than in the other, but without being completely separated. In our hands, no such perfect separation has been observed until now between any two cancer patient/control groups, for any of the degradation products of any substrate Figure 6 | MALDI-TOF MS overlays of selected ion peaks corresponding to C3f_ 13 C degradation products in sera from thyroid cancer patients and healthy controls. Selected degradation products derived from 13 C-labeled C3f (40 pmol starting material), following a 3-h incubation in separate 20 ml aliquots of each of the individual samples, are shown. Spectra were obtained, aligned and normalized as described under the 'Signal processing and quantitation' section (Steps 64-69), and are displayed using the MassSpectraViewer. Each of the three overlays contains 96 spectra with normalized intensities: 48 controls (in blue) and 48 thyroid cancer patients (red). The 'C-13' isotope from the isotopic envelope is shown for each peptide-ion peak. Substrate sequence, position of the label (first Leu-in blue) and mono-isotopic molecular mass are listed in Table 1 .
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